Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Valeant adds Jeffrey Ubben to boardValeant has appointed Jeffrey Ubben, CEO of ValueAct Capital, as a member of its board of directors.

Ubben joins at a crucial time for Valeant as the company tries to take over Allergan, the marketer of Botox and other aesthetic and health products.

The company will benefit from Ubben's rich business experience, which includes founding the investment management firm ValueAct Capital.

Ubben commented on the recent attempts to acquire Allergan, which have prompted a backlash, with Allergan questioning Valeant's business model.

“Valeant has become significantly undervalued on a standalone basis due to recent unjustified attacks on the company,” said Ubben. “We are strongly supportive of the Allergan-Valeant combination in light of their perfect strategic fit and the potential to create enormous shareholder value for both companies.”

2nd October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics